Emergence of plasmid-mediated quinolone-resistant determinants in Klebsiella pneumoniae isolates from Tehran and Qazvin provinces, Iran by Peymani, Amir et al.
J prev med hyg 2015; 56: e61-e65
E61
Background. Plasmid-mediated quinolone resistance is an 
increasing clinical concern, globally. The major objective of the 
present study was to identify the qnr-encoding genes among the 
quinolone non-susceptible K. pneumoniae isolates obtained from 
two provinces in Iran.
Methods. A total of 200 K. pneumoniae isolates were obtained 
from hospitals of Qazvin and Tehran, Iran. The identification of 
bacterial isolates was carried out by standard laboratory methods 
and API 20E strips. Susceptibility to quinolone compounds were 
examined by standard Kirby-Bauer disk diffusion method accord-
ing to the CLSI guideline. PCR and sequencing were employed to 
detect qnrA, qnrB and qnrS-encoding genes. 
Results. Of 200 K. pneumoniae isolates, 124 (62%) were non-
susceptible to quinolone compounds among those 66 (53.2%) and 
58 (46.8%) isolates showed high and low-level quinolone resist-
ance rates, respectively. Out of 124 quinolone non-susceptible 
isolates, qnr-encoding genes were present in 49 (39.5%) isolates 
with qnrB1 (30.6%) as the most dominant gene followed by qnrB4 
(9.7%), and qnrS1 (1.6%) either alone or in combination. 
Conclusions. This study, for the first time, revealed the high 
appearance of qnrB1, qnrS1 and qnrB4 genes among the clinical 
isolates of K. pneumoniae in Iran. Therefore, the application of 
proper infection control measures and well-established antibiotic 
administration guideline should be strictly considered within our 
medical centers.
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Summary
Introduction
Klebsiella pneumoniae (K. pneumoniae) is an oppor-
tunistic pathogen causing several nosocomial infections 
such as urinary tract infections, pneumonia, septice-
mia, and soft tissue infections [1]. This organism is also 
known as a community-acquired potential pathogen [2]. 
Health care associated infection caused by this organ-
ism has been linked to high mortality and morbidity es-
pecially among the patients admitted to intensive care 
units [3, 4].
Quinolones are a group of synthetic antibacterial agents 
that are widely used in routine clinical practice [5]. The 
new quinolones compounds (6-fluoroquinolones) ex-
hibit broad spectrum of antibacterial activity against 
Gram-negative, mycobacterial pathogens, and anaer-
obes. Moreover, these agents show a good-to-moderate 
oral absorption and tissue penetration with favorable 
pharmacokinetics in humans, creating desirable clinical 
efficacy in treating many kinds of infections [6, 7]. Qui-
nolones inhibit the function of bacterial DNA gyrase and 
topoisomerase IV  [8]. While the first and second gen-
eration fluoroquinolones selectively inhibit the topoi-
somerase II ligase domain or DNA gyrase activity, the 
quinolones of third and fourth generations are with more 
tendency for topoisomerase IV ligase [9]. Excessive and 
inappropriate administration of antimicrobial agents 
such as quinolones has increased the emergence of mul-
tidrug resistant K. pneumoniae isolates which makes the 
process of antimicrobial therapy to become marginal 
and problematic [10, 11]. In recent years, several stud-
ies have demonstrated that the appearance of quinolone-
resistant K. pneumoniae is rising at a faster rate, world-
wide [12-15]. Infections caused by resistant organisms 
are often due to extensive cross-resistance with other 
antimicrobials, including beta-lactams and aminoglyco-
sides [16]. Quinolone resistance in Enterobacteriaceae 
mainly occurs through chromosomal mutations in the 
genes coding for DNA gyrase and topoisomerase IV, 
changes in outer membrane and efflux proteins or in 
their regulatory mechanisms [17]. Findings from recent 
studies show that plasmid-mediated resistance, associ-
ated with the pentapeptide proteins of the qnr family, 
might play a crucial role in quinolone compound re-
sistance [18]. Three major groups of qnr determinants, 
qnrA, qnrB, and qnrS, are increasingly being identified 
in the clinical isolates of various enterobacterial species, 
worldwide  [19]. It was in 1998 that the first plasmid-
mediated quinolone resistance determinant, qnrA, was 
reported in a Klebsiella pneumoniae strain from the 
United States [20]. Since then two qnr determinants, qn-
rB and qnrS have been discovered in other Enterobacte-
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riaceae species such as Citrobacter Koseri, Escherichia 
coli, Enterobacter cloacae, and Klebsiella pneumoniae 
from Asia and Europe [21-24]. To date, there has been 
no report for the frequency of qnr genes among K. pneu-
moniae isolates in Iran. In the current study, for the first 
time, we described the frequency of qnr determinants 
(qnrA, qnrB, and qnrS) among the isolates of quinolone 
non-susceptible K. pneumoniae collected from hospitals 
of Qazvin and Tehran provinces.
Methods
Bacterial isolates and Antimicrobial 
susceptibility
In this descriptive study, a total of 200 clinical isolates of 
K. pneumoniae were collected from hospitalized patients 
in several teaching hospitals in Tehran and Qazvin dur-
ing 2012-2013. The isolates were obtained from differ-
ent clinical specimens including urine, wound, trachea, 
secretions, blood, and ascites. All isolates were identi-
fied by standard laboratory methods and confirmed with 
the API 20 E (bioMérieux, France) strips. All isolates 
were kept  at -70°C in trypticase soy broth containing 
20% glycerol and subcultured twice before testing. The 
mean age of patients (77 (38.5%) male and 123 (61.5%) 
female) was 51.7±17.4 (range17-83) years. Written in-
formed consent was obtained from all subjects enrolled 
in this study. Kirby-Bauer disk diffusion technique was 
performed according to the CLSI guideline to identify 
quinolone resistance  using nalidixic acid (30µg), cipro-
floxacin (5 µg), gatifloxacin (5 µg), norfloxacin (10 µg), 
and levofloxacin (5 µg) disks [25]. In this study the iso-
lates were classified either as high-level quinolone resist-
ant if the resistance to both nalidixic acid and ciprofloxa-
cin disks was observed or low-level quinolone resistant 
in the cases of resistance to nalidixic acid, presence of 
intermediate isolates or ciprofloxacin-susceptible or-
ganisms [26]. Antibiotic disks were purchased from the 
Mast (Mast Diagnostics Group Ltd, Merseyside, UK). E. 
coli ATCC 25922 and Pseudomonas aeruginosa ATCC 
27853 were used as quality control strains in antimicro-
bial susceptibility testing.
Detection of qnr determinants
Detection of qnrA, qnrB, and qnrS plasmid-mediated 
quinolone resistance genes was performed using PCR 
and specific primers (Tab. I). Plasmid DNA was ex-
tracted by plasmid mini extraction kit (Bioneer Com-
pany, South Korea). PCR amplifications were applied in 
a thermocycler (Applied Biosystems, USA) as follows: 
95ºC for 5min and 35 cycles of 1min at 95ºC, 1min at 
specific annealing temperature for each primer and 1min 
at 72ºC. A final extension step of 10 min at 72ºC was 
performed. Amplification reactions were prepared in a 
total volume of 25μl (24μl of PCR master mix plus 1μl 
of template DNA) including 5ng of genomic DNA, 2.0U 
of Taq DNA polymerase, 10mM dNTP mix at a final 
concentration of 0.2mM, 50mM MgCl2 at a final con-
centration of 1.5mM, 1μM of each primer, and 1X PCR 
buffer (final concentration). PCR products were electro-
phoresed on 1% agarose gel at 100 volts and later stained 
with ethidium bromide solution and finally visualized in 
a gel documentation system (UVtec, UK).  The purified 
PCR products were sequenced by the Macrogen Com-
pany (Seoul, South Korea) and the sequence alignment 
and analysis were performed online using the BLAST 
program of the National Center for Biotechnology Infor-
mation (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Data were summarized using mean ± SD (standard de-
viation), proportional frequency and confidence interval 
for microbiological, clinical, and demographic charac-
teristics. All analyses were carried out using a Statisti-
cal Software Package, SPSS for windows version 16.0 
(Chicago, IL, USA).
Results 
In this study, the bacterial isolates were recovered 
from different clinical specimens including urine (110-
55.0%), trachea (59-29.5%), wound (18-9.0%), blood 
(8-4%), and ascites (5-2.5%). These isolates were ob-
tained from the patients admitted to intensive care units 
(96-48.0%), internal medicine (54-27.0%), infectious 
diseases (35-17.5%), surgery (13-6.5%), and orthopae-
dic (2-1.0%) wards. The results of antimicrobial suscep-
tibility testing showed the resistance rates against the 
antimicrobial agents used in our study varied between 
20% and 58%. Overall, nalidixic acid (58%) and cipro-
floxacin (34.5%) revealed the highest rates of resistance 
among the antimicrobials tested whereas levofloxacin 
and norfloxacin also demonstrated high susceptibility 
rates of 80% and 77%, respectively (Tab. II). In total, 
Tab. I. The primers used for detection of qnr genes in K. pneumoniae isolated from Qazvin and Tehran hospitals.
PCR targets Primer sequence (5’-3’) Annealing temperatures (ºC) References
qnrA1–6
F: ACgCCAggATTTgAgTgAC
r: CCAggCACAgATCTTgAC
49 27
qnrB1-3, 5, 6, 8
F: ggCACTgAATTTATCggC
r: TCCgAATTggTCAgATCg
49 27
qnrB4
F: AgTTgTgATCTCTCCATggC
r: CggATATCTAAATCgCCCAg
53 27
qnrS1–2
F: CCTACAATCATACATATCggC
r: gCTTCgAgAATCAgTTCTTgC
53 27
Qnr determinants in K. pneumoniae
E63
66 (53.2%) and 58 (46.8%) of isolates showed high and 
low-level quinolone resistance, respectively.
PCR and sequencing showed the presence of qnr-en-
coding genes in 49 (39.5%) of quinolone non-suscep-
tible  K. pneumoniae isolates among those qnrB1 (38-
30.6%) was the most common gene followed by qnrB4 
(12-9.7%) and qnrS1 (2-1.6%) genes either alone or in 
combination. The study isolates were negative for qnrA 
gene. As shown in Table III, qnrB1 was found to coex-
ist with qnrB4 in 3 (2.4%) isolates. Overall, 25 (37.9%) 
high level quinolone resistant isolates carried qnr genes 
in which 19 (28.8%), 4 (6.1%), and 2 (3%) isolates car-
ried qnrB1, qnrB4, and qnrS1 genes, respectively. In ad-
dition, 24 (41.4%) low level quinolone resistant isolates 
were positive for qnr genes among those 19 (32.8%) iso-
lates carried qnrB1 gene followed by qnrB4 in 8 (13.8%) 
isolates. Among the high and low-level quinolone resist-
ance isolates, qnrB1 was the most frequent gene com-
pared to other genes. Table IV shows that qnr-positive 
isolates were mostly recovered from urine (42.9%) fol-
lowed by trachea secretion (36.7%) samples. The pa-
tients affected by these organisms were mostly admitted 
to ICU (59.2%) and internal medicine (20.4%) wards.
Discussion
K. pneumoniae is being increasingly recognized as a 
clinically significant nosocomial pathogen [1]. Quinolo-
nes are among the most commonly administered antimi-
crobials routinely used for the treatment of serious infec-
tions caused by K. pneumoniae and other members of 
the genus Enterobacteriaceae  [6]. However, the devel-
opment of resistance to these antibiotics makes the treat-
ment decision difficult, leading to treatment failures  [5]. 
In recent years, plasmid mediated quinolone resistance 
among enterobacterial isolates has been reported in sev-
eral studies, worldwide. However, the number of reports 
on prevalence of qnr genes among Iranian enterobacte-
ria isolates is only limited to few studies [28, 29]. 
In the present study, 58% and 34.5% of isolates were 
fully or intermediate resistant to nalidixic acid and cipro-
floxacin, respectively. These findings were higher than 
the two previously conducted studies in Iran. Raei et al 
demonstrated that 36.2% and 34.1% of urinary K. pneu-
moniae iso lates were resistant to ciprofloxacin and nali-
dixic acid, respectively [30]. In another study from Iran, 
Zamani et al found that 28.57% and 23.8% of Klebsiella 
spp. were resistant to nalidixic acid and ciprofloxacin, 
respectively [31]. Hence, the emergence of resistant iso-
lates against broad spectrum antibacterial agents in our 
hospital settings seems to be linked with improper and 
widespread administration of these antibiotics. 
The present study demonstrates a high prevalence 
(39.5%) for plasmid-mediated quinolone resistance 
determinants among quinolone non-susceptible K. 
pneumoniae isolates in Iran. The prevalence rate found 
in our study is higher than those reported by Kim et 
al from Korea (10%)  [32], Wang et al from China 
(11.9%) [33], Dahmen et al from Tunisia (16%) [34], 
Yan et al  from China (16.2%)  [35], and Wang et al 
from the United States (11.1%) [36] but still lower than 
that found by Bouchakour et al in Morocco in which 
50% of ESBL-producing K. pneumoniae  isolates were 
shown to carry qnr determinants  [37].  This might be 
indicative of a rising trend in the rate of plasmid medi-
ated quinolone resistance among the genus of Entero-
bacteriaceae.  
In the current study, 25% of qnr-positive isolates were 
shown to have high level quinolone resistance. As plas-
mid mediated quinolone resistance determinants pro-
duce only low-level resistance to quinolones, it can be 
hypothesized that high level resistant pattern is possibly 
Tab. II. Antibiotic susceptibility of K. pneumoniae against quinolone 
compounds.
Antimicrobial 
agents
Resistance
n (%) [CI]
Intermediate
n (%) [CI]
Susceptible
n (%) [CI]
Nalidixic acid
83(41.5)  
[34.7-48.3]
33(16.5)  
[11.4-21.6]
84(42)  
[35.2-48.8]
Ciprofloxacin
53(27)  
[20.8-33.2]
15(7.5)  
[3.8-11.2]
131(65.5)  
[58.9-72.1]
gatifloxacin
39(19.5)  
[14-25]
27(13.5)  
[8.8-18.2]
134(67)  
[60.5-73.5]
Norfloxacin
37(18.5)  
[13.1-23.9]
9(4.5)  
[1.6-7.4]
154(77)  
[71.2-82.8]
Levofloxacin
36(18)  
[12.7-23.3]
4(2)  
[0.1-3.9]
160(80)  
[74.5-85.5]
CI = 95% Confidence interval
Tab. III. distribution of qnrB1, qnrB4, and qnrS1 genes among qnr-
positive K. pneumoniae isolates.
qnr-encoding genes
N of isolates
n (%) [CI]
qnrB1 35 (28.2%) [20.3-36.1]
qnrB4 9 (7.3%) [2.7-11.9]
qnrS1 2 (1.6%) [0-3.8]
qnrB1+qnrB4 3 (2.4%) [0-5.1]
qnr negative 75(60.5%) [51.9-69.1]
Total 124 (100%) 
 CI: 95% Confidence interval
Tab. IV. Frequency of qnr-positive K. pneumoniae isolates based on 
hospital wards and source of Specimens (n = 49).
Wards
Nº of isolates 
n (%) [CI]
Specimens
Nº of isolates
n (%) [CI]
ICU
29 (59.2%)  
[45.4-73]
Urine
21 (42.9%)  
[29-56.8]
Internal 
medicine
10 (20.4%)  
[9.1-31.7]
Trachea
18 (36.7%)  
[23.2-50.2]
Infectious 
diseases
8 (16.3%)  
[6-26.6]
Wound
6 (12.2%)  
[3-21.4]
Surgery
2 (4.1%)  
[0-9.7]
Blood
1 (2%)  
[0-5.9]
Orthopedic - Ascites
3 (6.1%)  
[0-12.8]
 ICU: Intensive Care Unit
 CI: 95% Confidence interval
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caused by another mechanisms such as chromosomal 
mutation which was not evaluated in the present study. 
Considering the findings of the present study, it is obvi-
ous that most qnr-positive K. pneumoniae isolates were 
mostly obtained from the patients admitted to ICUs. 
Long term ICU stay, broad spectrum antibiotics intake, 
chronic underlying conditions, and the application of 
invasive techniques and devices probably make the pa-
tients more susceptible to infections caused by these re-
sistant organisms.
In the present study, 30.6%, 9.7%, and 1.6% of qui-
nolone non-susceptible K. pneumoniae isolates carried 
qnrB1, qnrB4, and qnrS1 genes alone or in combina-
tion, respectively. We believe that this is the first report 
of qnrS1, qnrB4, and qnrB1 genes among the clinical 
isolates of K. pneumoniae collected from two distinct 
provinces of Iran. In a study by Pakzad et al reported 
from Iran, 9 (37.5%) and 4 (20.8%) of ESBL-producing 
E. coli isolates were positive for qnrA and qnrB genes, 
respectively  [29]. The presence of qnrA (25.8%), qn-
rB1 (1.17%), and qnrS (1.17%) genes among ESBL-
producing Salmonella spp. was also reported in a study 
by Saboohi et al from Iran [28]. In another study from 
Iran, Seyedpour et al showed that 30.4% of commu-
nity isolates of K. pneumoniae harbored qnr and/or aac 
(6’)-Ib-cr genes [38]. In Taiwan, Wu et al described 
the presence of qnrB4 (3.6%), qnrS1 (2.8, and qnrB2 
(2.3%) genes in the clinical isolates of K. pneumoni-
ae  [39]. Robicsek et al in the United States reported 
that 14% and 6% of ceftazidime-resistant K. pneumo-
niae isolates harbored qnrA and qnrB genes, respec-
tively  [40]. Dahmen et al from Tunisia showed qnrA 
was more prevalent among K. pneumoniae isolates 
whereas qnrB1 was the most prevalent genes among 
E. cloacae isolates followed by qnrB2 and qnrS1 [34]. 
Similarly, Yan et al in their report from China demon-
strated that 8.1%, 4.1%, and 4.1% of ESBL-producing 
K. pneumoniae isolates were positive for qnrA, qnrB, 
and qnrS genes, respectively [35]. Finally, Wang et al 
in a study carried out in China reported that 62 (15.1%), 
25 (6.1%), and 10 (2.4%) of ESBL-producing K. pneu-
moniae isolates were positive for qnrS, qnrB, and qnrA 
genes, respectively [33].
Conclusions
Findings of the present study reveal a high prevalence 
for plasmid-mediated quinolones resistance due to qnr 
genes among the clinical isolates of K. pneumoniae in 
Iran. The  appearance and spread of such resilient or-
ganisms within the medical centers around the country 
not only brings about issues of great concern for human 
health but also raises questions on how to achieve a 
successful antibiotic therapy through planning a com-
prehensive infection control guideline to avoid further 
spread of these resistant organisms within our medical 
settings. Our data also highlights the necessity for es-
tablishing an appropriate infection control strategy and 
sensible antibiotic therapy. 
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